IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Aug 3, 2023 · 10-Q · 34 days after period end · 0000950170-23-038042
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$4.89M | -$16.56M | -$21.75M | -$17.61M |
| EPS Diluted | -$0.14 | -$0.51 | -$0.74 | -$0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 3, 2023 · 34 d after period end
